The Organisation for Oncology and Translational Research (OOTR) was established in 2002 by Dr Louis WC Chow and Dr Masakazu Toi to gather medical professionals from different countries to work together in translational research as one of the missions of the organisation. Therefore, we seek to create networking among oncologists and develop effective interaction among the most advanced academic institutions throughout the world in order to conduct clinical trials and translational research together. Several clinical trials evaluating the use of neoadjuvant therapy for breast cancer have been designed and conducted for the past 10 years in the OOTR. The design of these studies has shifted from evaluating the efficacy and safety of new anticancer therapies and exploring new predictive and prognostic biomarkers to overcoming and unveiling the mechanism of tumor resistance as well as compiling predictive models for treatment response. This article briefly summarizes the concept and development of the OOTR clinical trial designs.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Chow, L. W., & Toi, M. (2012). The clinical trials of the organisation for oncology and translational research (ootr). International Journal of Biological Markers, 27(4). https://doi.org/10.5301/JBM.2012.10371